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Previewsrecurrence, but also the opportunity to
identify novel targets in the dominant
clone at recurrence, some of which may
be eminently and imminently targetable
using existing therapeutics. Considering
the lethality of glioblastoma, we believe
the time has come for routine biopsy at
relapse in settings where targeted agents
will be employed, with the goal of identi-
fying targets still present at recurrence,
and eventually to target pathways en-
riched at relapse upfront as anticipatory
therapy.
REFERENCES
Aparicio, S., andCaldas, C. (2013). N. Engl. J. Med.
368, 842–851.Ding, L., Ley, T.J., Larson, D.E., Miller, C.A., Ko-
boldt, D.C., Welch, J.S., Ritchey, J.K., Young,
M.A., Lamprecht, T., McLellan, M.D., et al. (2012).
Nature 481, 506–510.
Eleveld, T.F., Oldridge, D.A., Bernard, V., Koster,
J., Daage, L.C., Diskin, S.J., Schild, L., Bentahar,
N.B., Bellini, A., Chicard, M., et al. (2015). Nat.
Genet. 47, 864–871.
Hegi, M.E., Diserens, A.C., Gorlia, T., Hamou, M.F.,
de Tribolet, N., Weller, M., Kros, J.M., Hainfellner,
J.A., Mason, W., Mariani, L., et al. (2005). N. Engl.
J. Med. 352, 997–1003.
Johnson, B.E., Mazor, T., Hong, C., Barnes, M., Ai-
hara, K., McLean, C.Y., Fouse, S.D., Yamamoto,
S., Ueda, H., Tatsuno, K., et al. (2014). Science
343, 189–193.
Kim, J., Lee, I.-H., Cho, H.J., Park, C.-K., Jung, Y.-
S., Kim, Y., Nam, S.H., Kim, B.S., Johnson, M.D.,
Kong, D.-S., et al. (2015a). Cancer Cell 28, this
issue, 318–328.Cancer Cell 28, SeKim, H., Zheng, S., Amini, S.S., Virk, S.M., Mikkel-
sen, T., Brat, D.J., Grimsby, J., Sougnez, C.,
Muller, F., Hu, J., et al. (2015b). Genome Res. 25,
316–327.
Mazor, T., Pankov, A., Johnson, B.E., Hong, C.,
Hamilton, E.G., Bell, R.J.A., Smirnov, I.V., Reis,
G.F., Phillips, J.J., Barnes, M.J., et al. (2015). Can-
cer Cell 28, this issue, 307–317.
Schramm, A., Ko¨ster, J., Assenov, Y., Althoff, K.,
Peifer, M., Mahlow, E., Odersky, A., Beisser, D.,
Ernst, C., Henssen, A.G., et al. (2015). Nat. Genet.
47, 872–877.
Stupp, R., Mason, W.P., van den Bent, M.J.,
Weller, M., Fisher, B., Taphoorn, M.J., Belanger,
K., Brandes, A.A., Marosi, C., Bogdahn, U., et al.;
European Organisation for Research and Treat-
ment of Cancer Brain Tumor and Radiotherapy
Groups; National Cancer Institute of Canada Clin-
ical Trials Group (2005). N. Engl. J. Med. 352,
987–996.Keeping It in the Family: ATRX Loss Promotes
Persistent Sister Telomere Cohesion
in ALT Cancer CellsCaitlin M. Roake1,2 and Steven E. Artandi1,2,3,*
1Cancer Biology Program, Stanford University School of Medicine, Stanford, CA 94305, USA
2Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
3Department of Biochemistry, Stanford University School of Medicine, Stanford, CA 94305, USA
*Correspondence: sartandi@stanford.edu
http://dx.doi.org/10.1016/j.ccell.2015.08.005
In this issue ofCancer Cell, Ramamoorthy and Smith report that cancer cells that maintain their chromosome
ends through alternative lengthening of telomeres (ALT) display persistent sister telomere cohesion. This de-
layed resolution of sister telomere cohesion depends upon the loss of ATRX and its histone-sequestering
function and is associated with increased recombination between sister telomeres.Telomeres in many human somatic cells
shorten with each round of replication,
whereas telomeres are maintained with
cell division in cancer cells. In 90% of
human tumors, the enzyme telomerase
is responsible for telomere maintenance
and cellular immortalization. However,
the remaining 10% of cancers lack telo-
merase expression and, in these cells,
the alternative lengthening of telomeres
(ALT) pathway counteracts normal short-
ening. ALT cells use a recombination-
based mechanism to increase the length
of telomeric DNA, but, for recombination
to occur, telomeres must encounter each
other in the nucleoplasm. One meansfor connecting two chromosome ends
in the space of the nucleus involves
one telomere traveling directionally
across large distances to find another,
using the machinery that normally drives
meiotic chromosome synapsis (Cho
et al., 2014). In this model, telomeres
can rapidly travel up to 5 mm to cluster
together and recombine. Alternatively,
telomeres can exploit the fact that,
after telomere replication in S-phase,
each chromosome end has a nearby
sister telomere that can serve as a tem-
plate for recombination at a distance of
only 0.5 mm. Mitotic cells typically use
sister chromatid recombination insteadof recombination between homologs.
Although ALT clearly relies on telomere-
telomere recombination, the relative
proportion of recombination between
sisters versus recombination between
homologs is unknown (Dunham et al.,
2000)
In this issue ofCancer Cell, Ramamoor-
thy and Smith (2015) observe that, in ALT
cell lines, sister telomere cohesions that
normally dissolve after S-phase persist
into mitosis, leading them to hypothesize
that this persistent cohesion allows the
telomeres to preferentially serve as a tem-
plate for recombination. Indeed, one of
the core molecular features of ALT cellsptember 14, 2015 ª2015 Elsevier Inc. 277
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Figure 1. ATRX Loss Contributes to Both
Inter-chromosomal and Sister Telomere
Recombination
Loss of ATRX is linked with both increased sister
telomere recombination and increased inter-chro-
mosomal telomere recombination. In the first
case, ATRX loss causes delayed resolution of sis-
ter telomere cohesion. This persistent cohesion is
associated with increased recombination between
sister telomeres. Both of these phenotypes can be
suppressed with overexpression of tankyrase, a
telomere-associated protein involved in sister telo-
mere resolution. In the second case, telomeres
recombine with a telomere on another chromo-
some, often moving rapidly over large inter-nuclear
distances with the help of Rad51 and the meiotic
proteins Hop2 and Mnd1. However, in either
case, loss of ATRX is not sufficient to trigger the
recombination of telomeres and other as-yet-un-
known steps are required.
Cancer Cell
Previewsis an elevated rate of telomere sister chro-
matid exchange (T-SCE) (London˜o-Val-
lejo et al., 2004). This raises the possibility
that ALT T-SCE is enhanced by these
persistent telomere cohesions.
The SWI/SNF-like ATPase ATRX is lost
in a majority of ALT-positive cell lines
(Heaphy et al., 2011; Lovejoy et al.,
2012). ATRX has been shown to have
diverse functions, from altering patterns
of methylation at repetitive genomic se-
quences to enhancing histone exchange.
To examine the role of ATRX in persistent
telomere cohesion, Ramamoorthy and
Smith (2015) show that reintroduction of
ATRX into ALT cell lines causes resolution
of telomere cohesion and lower rates of
T-SCE. Conversely, knockdown of ATRX
in telomerase positive cell lines triggers
the appearance of persistent sister telo-
mere cohesion (see Figure 1). The authors
make the important observation that loss
of ATRX therefore phenocopies loss of
tankyrase, a telomeric poly(adenosine
diphosphate-ribose) polymerase (PARP),
whose depletion in cancer cells leads to278 Cancer Cell 28, September 14, 2015 ª20enhanced sister telomere cohesion and
cellular arrest in anaphase of mitosis
(Dynek and Smith, 2004). They show that
overexpression of tankyrase restores
normal resolution of sister telomere
cohesion in ALT cancer cells in a similar
fashion to overexpression of ATRX
(see Figure 1) (Ramamoorthy and Smith,
2015).
The best characterized function of
ATRX is its histone chaperone activity;
ATRX and Daxx have each been shown
to deposit histone H3.3 at repetitive se-
quences in the genome (Lewis et al.,
2010). Additionally, ATRX binds to and
negatively regulates deposition of the
variant histone macroH2A1.1 at alpha
globin sequences (Ratnakumar et al.,
2012). Ramamoorthy et al. provide evi-
dence that this histone binding domain
of ATRX can repress the T-SCE pheno-
type and show that, in the absence of
ATRX, macroH2A1.1 is bound to and
negatively regulates tankyrase preventing
its normal association with telomeres and
its role in resolving sister telomere cohe-
sions (Ramamoorthy and Smith, 2015).
These data lead the authors to test the
consequences of forcing resolution of sis-
ter telomeres in ALT cells. They employ a
systemwhere telomeres are tagged using
lacO repeats to follow inter-chromosomal
telomeric recombination events. Using
overexpressed tankyrase to overcome
tankyrase sequestration in ALT cells, the
authors find that resolution of sister telo-
mere cohesion is accompanied by rapid
inter-chromosomal exchanges indicated
by proliferation of the lacO sequences to
additional telomeres. Over time, however,
cells with the greatest number of lacO-
marked telomeres are preferentially lost,
leading the authors to speculate that this
rapid inter-chromosomal recombination
is detrimental to cellular viability (Rama-
moorthy and Smith, 2015).
The data also raise many questions. Is
T-SCE the most common or preferred
route of telomere recombination in an
ALT cell? In which instances would a telo-
mere travel a greater distance to recom-
bine with a telomere on another chromo-
some? What are the cellular conditions
and machinery that would favor one route
over another? In a studybyGreenberg and
colleagues, induction of damage at telo-
meres using a Fok1 endonuclease fused
to a telomeric protein caused rapid telo-
mere movement and inter-chromosomal15 Elsevier Inc.telomere recombination (Cho et al.,
2014). Perhaps inter-chromosomal telo-
mere recombination is favored when a
telomere is damaged or when sister telo-
mere recombination is inefficient.
Intriguingly, Karlseder and colleagues
recently reported that depletion of the his-
tone chaperone ASF-1 leads to hallmarks
of ALT including promyelocytic leukemia
(PML) bodies, extrachromosomal telo-
meric DNA, increased rates of T-SCE,
and inter-telomeric recombination (O’Sul-
livan et al., 2014). Together with the role of
ATRX/DAX in ALT, these findings solidify
the idea that altered chromatin dynamics
are key in the ALT mechanism. It would
be interesting to examine whether the
increased rates of T-SCE in ASF-1 knock-
down cells are also mediated by persis-
tent sister telomere cohesion and can be
suppressed by overexpression of ATRX
or tankyrase. Exploring these questions
may help us understand more broadly
the connection between telomeric recom-
bination and histone chaperones.
Additionally, the exact causal role of
ATRX loss in ALT cells has yet to be eluci-
dated, and this manuscript adds another
piece to the puzzle. It seems increasingly
likely that altered chromatin at telomeres
in ALT cells lacking ATRX contributes
to rendering the telomeres more recombi-
nogenic. The new data presented in this
manuscript suggest that another possible
role of ATRX loss is to promote prolonged
cohesion time between sister telomeres
and encourage their recombination
through physical interaction. However,
despite the fact that Ramamoorthy and
Smith (2015) show that ATRX loss is suffi-
cient to promote sister telomere cohe-
sion, others have found that loss of
ATRX is not sufficient alone to induce
T-SCE formation or the full ALT state
(Lovejoy et al., 2012). Furthermore,
the nature of this cohesion induced
upon ATRX knockdown remains to be
explored. Is it mediated as in non-ALT
cancer cells by the ring complex cohesin
or does it reflect more direct association,
such as strand invasion and the actual
process of homologous recombination?
It seems that additional events beyond
ATRX loss are likely required for cells to
achieve full blown ALT, and it will be
important to determine specifically the
steps involved.
These new findings connect a telo-
mere-associated protein, tankyrase, with
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Previewsthe ATRX/Daxx pathway in ALT. It has
been shown that tankyrase loss in non-
ALT cells causes persistent telomere
cohesions and cell arrest in anaphase of
mitosis (Dynek and Smith, 2004). How
do ALT cells with delayed resolution of
sister telomere cohesion manage to
circumvent this blockade in the cell
cycle? Do other shelterin members, such
as the tankyrase-binding partner TRF1,
play any role in this aspect of the ALT
pathway?
In ALT, the telomeres must first find
each other to recombine, and they have
a choice whether to shop locally or to
sample further afield. What influences
this choice and what the consequences
of this decision are will help us tobetter understand the role of telomeric
recombination in ALT and determine
how telomerase-negative cancer cells
acquire immortal growth properties.REFERENCES
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Current BRAF inhibitors block signaling from monomeric BRAFV600E, but not from oncogenic RAS, which
requires RAF dimerization. In this issue of Cancer Cell, Yao and colleagues investigate why current drugs
are ineffective against RAF dimers, while Peng and colleagues describe a pan-RAF inhibitor targeting both
monomeric and dimeric RAF.Mutations in RAS family members and
BRAF are important cancer drivers in
>30% of human malignancies, and up-
regulation of canonical RAS/RAF/MEK/
ERK signaling is observed in the majority
of tumors. The extensive nature of onco-
genic signaling through this pathway
has made the identification of RAS
and RAF inhibitors a top priority of
drug discovery programs for over two
decades. Although agents that block
RAS activity remain elusive, the devel-
opment of BRAF kinase inhibitors pro-
gressed steadily, with vemurafenib be-
ing the first to gain Food and Drug
Administration (FDA) approval in 2011
for the treatment of malignant melanomadriven by BRAFV600E, the most prevalent
BRAF mutation. Vemurafenib and other
first generation BRAF inhibitors exhibit
good efficacy against BRAFV600E and
have been touted as another success
story for targeted therapeutics; howev-
er, several early observations tempered
enthusiasm.
In particular, these drugs had little ac-
tivity against tumors possessing RASmu-
tations, even though the RAF kinases are
essential downstream effectors of RAS
(Fedorenko et al., 2011). In cell-based
assays, researchers further found that,
while these inhibitors were effective at
shutting down ERK signaling mediated
by BRAFV600E, they paradoxically upregu-lated ERK activity in the presence of
oncogenic RAS (Gibney et al., 2013).
Moreover, a subset of melanoma patients
treated with these drugs developed
secondary malignancies, many of which
arise from cells harboring pre-existing
RAS mutations. Finally, the effectiveness
of current BRAF inhibitors in treating
BRAFV600E-driven melanoma is short-
lived, with drug resistance invariably
developing, often as a result of ERK
cascade reactivation (Bucheit and Da-
vies, 2014).
The apparent limitations to the useful-
ness of these drugs, however, were not
without a silver lining in that they stimu-
lated a flurry of investigation that hasptember 14, 2015 ª2015 Elsevier Inc. 279
